medication is by far the most profitable drug from the Ely Lilly laboratory. It is reimbursed at 65%, while a box of 28 tablets costs 61.03 euros.
Status: Restricted in France since March 2017 (re-evaluation initiated in 2011), indication limited to angina pectoris in association (initial prescription reserved for cardiologists, annual re-evaluation); withdrawal of ENT and ophthalmological indications due to lack of efficacy and serious neurological risks.
– ZYBAN
Indications: smoking cessation.
Side effects: severe high blood pressure.
Status: Authorised in France (last updated 2025), without restrictions; monitoring for interactions